For the quarter ending 2026-03-31, ANIK had -$16,461K decrease in cash & cash equivalents over the period. -$6,277K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -5,056 | 292 | -2,329 | -8,843 |
| Depreciation | 1,407 | 1,318 | 1,391 | 2,663 |
| Amortization of acquisition related intangible assets | 0 | 0 | 12 | 345 |
| Non-cash operating lease cost | 464 | 499 | 495 | 1,067 |
| (gain) loss on sale of assets | - | 166 | - | - |
| Loss on impairment of long-lived assets | - | 0 | 0 | - |
| Stock-based compensation expense | 6,641 | 2,458 | 2,215 | 5,411 |
| Deferred income taxes | 108 | -25 | 3 | 15 |
| Provision for credit losses | -24 | 56 | 76 | 133 |
| Provision for inventory | 1,032 | 852 | 1,127 | 3,842 |
| Interest income on notes receivable | 179 | 472 | 79 | 345 |
| Gain on sale of assets | -904 | - | 451 | 505 |
| Accounts receivable | 2,180 | 1,545 | -1,294 | -659 |
| Inventories | 5,407 | 1,779 | 443 | -2,252 |
| Prepaid expenses, other current and long-term assets | 1,728 | -1,311 | -219 | -797 |
| Accounts payable | 745 | 877 | 231 | -1,066 |
| Operating lease liabilities | -468 | -471 | -480 | -1,045 |
| Accrued expenses, other current and long-term liabilities | -1,339 | 141 | 3,610 | -5,251 |
| Income taxes | 1,190 | 335 | -21 | -448 |
| Net cash used in operating activities | -4,846 | 4,637 | 6,870 | -319 |
| Proceeds from sale of intangible assets | - | 0 | 0 | 600 |
| Purchases of property and equipment | 1,431 | 648 | 1,887 | 4,291 |
| Proceeds from sale of parcus medical, net | 0 | 0 | 0 | 4,496 |
| Acquisition of intangible asset | - | 0 | 0 | - |
| Notes receivable | 192 | 846 | 155 | 328 |
| Net cash used in by investing activities | -1,239 | 198 | -1,732 | 1,133 |
| Proceeds from employee stock purchase program | - | 239 | 0 | 261 |
| Proceeds from exercises of equity awards | - | 0 | 0 | 0 |
| Repurchases of common stock | 8,690 | 5,514 | 0 | 3,971 |
| Cash paid for tax withheld on vested restricted stock awards | 1,657 | 4 | 13 | 1,549 |
| Net cash used in financing activities | -10,347 | -5,279 | -13 | -5,259 |
| Exchange rate impact on cash | -29 | -65 | -302 | 453 |
| Decrease in cash and cash equivalents | -16,461 | -509 | 4,823 | -3,992 |
| Cash and cash equivalents at beginning of period | 57,481 | 57,990 | 57,159 | - |
| Cash and cash equivalents at end of period | 41,020 | 57,481 | 57,990 | - |
Anika Therapeutics, Inc. (ANIK)
Anika Therapeutics, Inc. (ANIK)